{
  "document_id": "a1a0756b",
  "zip_file": "hyfg0257.zip",
  "category": "Presentations",
  "content_file": {
    "file_name": "hyfg0257.pdf",
    "file_path": "Presentations/hyfg0257.zip/hyfg0257.pdf",
    "extracted_text": "=== Page 1 ===\nDeveloping a path forward for market access \nNovember 2018 \nPrivileged: This presentation contains draft proposals for discussion by \nManagement and are subject to appropriate Purdue legal and regulatory review \nbefore they can be considered final. These materials are confidential and \nproprietary.\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 2 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nExecutive summary\n• To understand most appropriate rebate for Prime Part D, we first need to understand the \nfinancial position and likely bidding strategy for Collegium\n• Outside-in analysis of Collegium suggested an urgent need for at least $50Mn \nincremental net sales to support current strategy and stem losses \n• With only 2 ERO products in its portfolio, Collegium has limited options to close the gap, \naside from additional acquisitions\n• Given that Xtampza has very low market share and poor access right now, it would need to \nwin at least a couple of big commercial accounts at almost any rebate level, while \naiming for more profitable access elsewhere that matches strategy – e.g.,  Prime Part D given \nits strong regional focus\n• Based on the above assumptions, we assessed different contracting scenarios for Prime Part \nD, (e.g., continuing current access status as the exclusive Oxycodone ER, parity with Xtampza \nas preferred brand) and likely impact\n• Preliminary analyses indicate a break-even rebate of 45% to continue current access \nstatus, and a break-even rebate of 37% for parity with Xtampza\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 3 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium has been operating at a loss since its inception\n452\n217\n174\n172\n63\n70\n182\n80\nGross salesRebates\nCOGS\nR&D\n128\n24\nNet sales\nOther \nGTN \nreductio\nns\nSG&A\n-32\n9\n32\nLoss \nfrom \noperati\nons\n626\n252\n88\n287\nXtampza\nNucynta\nOverall \nRevenue and GTN reductions\nCosts and operating expenses\nCash at the end \nof Q3 2018:  \n~$140 Mn\nContext\n• Collegium has a \nportfolio of 2 \nproducts \nexclusively in \npain \nmanagement – \nXtampza and \nNucynta\n• R&D pipeline all \nearly life (Ph II or \nearlier) which is \nprimarily in  pain \nmanagement\n• Facing “finite” \nmarket for its \ncurrent portfolio, \ndriven by overall \nmarket decline \nand likely \ngenericization\n• Continues to\n2018 financial performance (estimated)\n$ Millions\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 4 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium would need to double current share of Xtampza in order to break even financially \n4\nPotential impact of doubling Xtampza share through exclusive \ncontracts with additional payors\n14\n32\n15\nCurrent \nloss \nfrom \noperatio\nns\n19\nGrowth \nfrom \nexisting \naccounts\nLoss \ndue to \nmarket \ndecline\n50\nGrowth \nfrom new \naccounts\nCOGS \nincrea\nse\n0\n2020 \noperat\ning \nincom\ne\nProjected 2020 Xtampza  financial \nperformance \n($ Millions)\nKey assumptions\n• ERO market \ncontinues to decline \nat -15% year on \nyear until 2020\n– Consistent with \nPurdue Finance \nassumption\n• Assume organic \ngrowth only (i.e., no \nBD deals)\n• SG&A remains the \nsame as current \nlevel\n• Nucynta sales \nremains the same as \ncurrent level – \noptimistic given it \nhas been declining \nin the past 2 years\nKey \nimplications\n• Clear need \nto quickly \nincrease \nsales to \nreassure \ninvestors or \nsales force \ndriven \nstrategy at \nrisk\n• Likely need \nbig wins \nquickly, \nrather than \nincremental\nly \nincreasing \nthrough \ntime\nDIRECTIONAL ESTIMATION\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 5 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium is more likely to bid aggressively on large national accounts to rapidly gain the $50M \nneeded to break even financially\n5\nNet sales1\n$M\n43\n11\n7\n11\n21\n31\n5\n5\n1\n1\n10\n10\n5\n1\n1\n1\n159\n18\n13\n4\n111\n73\n63\n17\n15\n6\n10\n9\n6\n113\n53\n17\n5\n545\n2019 contracting\nMarket \nsegment\nCommer-\ncial\nMedicare \nPart D\nCurrent status (FYE June 2018)\n1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; \n3 Assuming status carries over from 201807 period for \nthose accounts with OxyContin formulary access, status based on majority of lives; \n4 Excluding BCBS TN               5 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other prime accounts \n21%\n17%\n13%\n21%\n23%\n20%\n4%\n9%\n3%\n5%\n26%\n14%\n14%\n15%\n17%\n14%\nGross sales\n$M \nMarket \nShare\n11%\n7%\n6%\n2%\n2%\n1%\n1%\n1%\n1%\n1%\n11%\n5%\n2%\n1%\n1%\n0%\n54%\n% \nNet sales \nAccount\nExpress Scripts4\nCaremark\nOptumRx  - United Healthcare\nAetna Health Plans\nPrime Therapeutics - excl HCSC5\nPrime Therapeutics - HCSC\nCigna Healthcare\nProcare\nBCBS FL (Prime Therapeutics)\nIndependence BCBS (PA)\nCaremark\nOptumRx  - United Healthcare\nExpress Scripts\nPrime Therapeutics\nEnvisionRx Options\nTotal\nMedImpact\n2T Preferred\nNOF\nNOF\n2T Preferred\nNOF\n3T Preferred\n3T Pref PDP/MAPD NOF\nPref MAPD/PDP NOF\n2T Preferred\n2T Preferred\n2T Preferred \n2T Preferred\n2T Preferred\n2T Preferred\nNOF\n2T Preferred\n42%\n35%\n38%\n21%\n28%\n29%\n0%\n20%\n0%\n0%\n56%\n66%\n38%\n40%\n37%\n28%\nRebate2\nOxyContin\nXtampza ER3\nNon-preferred\nPreferred\nPreferred\nNon-preferred\nPreferred\nNOF\nPreferred\nNOF\nNOF\nNOF\nNon-preferred\nNon-preferred\nPreferred\nNon-preferred\nPreferred\nPreferred\n2019 formulary status\nCollegium is \nlikely to \ndouble down \non big \nnational \naccounts in \norder to \nachieve \nbreak-even\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\n11/04/2018\n11/16/2018\n12/07/2018\n12/14/2018\n11/19/2018\n2020 Bid \ndue date\nSOURCE: Purdue internal data, MMIT\nLives\n$M \n102\n26\n5\n191\n21\n112\n26\n21\n992\n12\n11\n7\n6\n258\n155\n20\n8\nGiven its size \nand regional \nfocus, Prime \ncould be a \npriority \naccount for \nCollegium, \nthough not \nlikely as \ngreat as the \nlarge \nnational \naccounts\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 6 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nPotential bidding options for Prime Part D\nPotential \nrebate\nInitial bid\nMaintain rebate \nrate of  40% to \ncontinue \ncurrent access \nstatus\nPotential payor \nfeedback\nAccepting the offer\nRequesting \nmoderate \nenhancement \n(≤45%)\nRequesting \nsignificant \nenhancement \n(>45%)\nProjected 2020 net \nsales ($M)\nOptions for Purdue\nReaching agreement\nIncreasing rebate \nrate by a couple of \npercentage points \nPulling back rebate \nfor parity with \nXtampza (30-35%) \nIncreasing rebate \nrate to >45%\nPulling back rebate \nfor parity with \nXtampza (35-40%)\nWalk away\n40%\n42%\n34%\n50%\n40%\n0%\n11.2\n10.8\n10.8\n8.9\n9.6\n10.2\nMore likely in case of very \naggressive Xtampza offer (i.e., \n>70% rebate) to become the \nexclusive Oxycodone ER\nLess 2020 \nnet sales vs. \nwalk-away,  \nbut could be \nmore \nattractive \nconsidering \nlong term \nfinancials \nand \nintangible \nimpacts \nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 7 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nAppendix\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 8 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nPrime contracting: 2020-2022 financial impact under different access scenarios\nAccess scenarios\nBoth Oxycontin and \nXtampza preferred \nXtampza preferred, \nOxycontin non-\npreferred\nContinue current \naccess status as \nexclusive preferred\noxycodone ER\nXtampza replacing \nOxycontin as \nexclusive preferred \nwith grandfathering\n51%\n41%\n34%\n5%\n0%\nOxycontin excluded \nwithout \ngrandfathering\n1\n2\n3\n4\nAssumed \nOxycontin rebate\nIncremental impact of exclusion  could be more detrimental in the longer term, due to continuing loss of share in a declining market\nShare by \nproduct, \n2020 Q4\n5\nPRIME\n15\n6\n1\n22\nOxycontin net sales2 ($M)\n1 Projected using a 3-4 ppt increase YoY on assumed likely rebate for scenarios 1-3\n2.Net sales shown exclude rebates and other gross-to-net reductions, i.e. donut hole and wholesales fees etc.\n5.8\n24.7\n10.8\n8.1\nXtampza\nOxycontin\nOther brands\n42%\n34%\n28%\n27%\n0%\n2020\n20221 \n22\n12\n7\n3\n7.1\n4.2\n10.8\n22.0\n4\n8\n11\n22\n3.4\n6.6\n10.8\n20.9\n8\n6\n8\n22\n5.6\n2.4\n10.8\n18.8\n9\n7\n6\n22\n2.0\n5.1\n17.3\n10.2\n2021\n2020\n2022\nLower blended rebate rate with fewer grandfathered \npatients  \nDeprioritize\nd scenario\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 9 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nPrime – continuing current access status or parity with Xtampza are best options to maintain \nappropriate access for patients while preserving best economics\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; \n2 Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  \n7.9\n11.2\n10.8\n11.5\n11.0\n7.2\n6.2\n11.2\n10.2\n6.6\n2020 access \nscenarios\nBoth \nOxycontin and \nXtampza \npreferred \nXtampza \npreferred, \nOxycontin \nnon-preferred\nContinue \ncurrent access \nstatus as  \nexclusive \npreferred\noxycodone ER\nXtampza \nreplacing \nOxycontin as \nexclusive \npreferred with \ngrandfathering\nOxycontin \nexcluded \nwithout \ngrandfatherin\ng\nXtampza net \nsales ($M)\n1\n2\n3\n4\n0%\n40%\n50%\n70%\n70%\nAssumed \nXtampza \nrebate\nImplication on Oxycontin bidding strategy\nexclusivity  could maximize net sales assuming no or reasonable increase in rebates, parity with Xtampza could be an attractive option – while exclusion w\n2.9\n1.8\n1.6\n1.1\n3.2\n0.8\n1.6\n2.1\nShare by \nproduct, 2020 \nQ4\nOther brand \nnet sales ($M)\n5\n8\n22\n7\n9\n5\n22\n8\n3\n10\n12\n4\n8\n11\n9\n22\n7\n6\n8\n5\n6\n8\n9\n22\n22\n9\n7\n6\n9\n3\n22\n22\n22\n8.8\n8.8\n7.3\n8.0\n7.7\n8.4\n9.2\n9.6\nOxycontin\nOther brands\nXtampza\nPRIME\n0.7\n1 6\n15\n22\n6.5\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nShar\ne \nshift\nBreak-\neven \nrebate2 \n37%\n48%\n32%\n37%\nN/A\n30%\n44%\n60%\n45%\nNet sales at min \nrebate1 ($M)\n42%\nRebate rate to keep \nPrime whole1 \n30%\n44%\n27%\n40%\nN/A\n24%\n36%\n40%\nNeed to \nmaintain \ncurrent \nrate a \nminimum\nBeing sim\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 10 ===\n \nDeveloping a path forward for market access \nNovember 2018 \nPrivileged: This presentation contains draft proposals for discussion by \nManagement and are subject to appropriate Purdue legal and regulatory review \nbefore they can be considered final. These materials are confidential and \nproprietary.\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 11 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nExecutive summary\n• To understand most appropriate rebate for Prime Part D, we first need to understand the \nfinancial position and likely bidding strategy for Collegium\n• Outside-in analysis of Collegium suggested an urgent need for at least $50Mn \nincremental net sales to support current strategy and stem losses \n• With only 2 ERO products in its portfolio, Collegium has limited options to close the gap, \naside from additional acquisitions\n• Given that Xtampza has very low market share and poor access right now, it would need to \nwin at least a couple of big commercial accounts at almost any rebate level, while \naiming for more profitable access elsewhere that matches strategy – e.g.,  Prime Part D given \nits strong regional focus\n• Based on the above assumptions, we assessed different contracting scenarios for Prime Part \nD, (e.g., continuing current access status as the exclusive Oxycodone ER, parity with Xtampza \nas preferred brand) and likely impact\n• Preliminary analyses indicate a break-even rebate of 45% to continue current access \nstatus, and a break-even rebate of 37% for parity with Xtampza\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 12 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium has been operating at a loss since its inception\n452\n217\n174\n172\n63\n70\n182\n80\nGross salesRebates\nCOGS\nR&D\n128\n24\nNet sales\nOther \nGTN \nreductio\nns\nSG&A\n-32\n9\n32\nLoss \nfrom \noperat\nons\n626\n252\n88\n287\nXtampza\nNucynta\nOve\nRevenue and GTN reductions\nCosts and operating expenses\nCash at the end \nof Q3 2018:  \n~$140 Mn\nContext\n• Collegium has a \nportfolio of 2 \nproducts \nexclusively in \npain \nmanagement – \nXtampza and \nNucynta\n• R&D pipeline all \nearly life (Ph II or \nearlier) which is \nprimarily in  pain \nmanagement\n• Facing “finite” \nmarket for its \ncurrent portfolio, \ndriven by overall \nmarket decline \nand likely \ngenericization\n• Continues to\n2018 financial performance (estimated)\n$ Millions\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 13 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium would need to double current share of Xtampza in order to break even financially \nPotential impact of doubling Xtampza share through exclusive \ncontracts with additional payors\n14\n32\n15\nCurrent \nloss \nfrom \noperatio\nns\n19\nGrowth \nfrom \nexisting \naccounts\nLoss \ndue to \nmarket \ndecline\n50\nGrowth \nfrom new \naccounts\nCOGS \nincrea\nse\n0\n2020 \noperat\ning \nincom\ne\nProjected 2020 Xtampza  financial \nperformance \n($ Millions)\nKey assumptions\n• ERO market \ncontinues to decline \nat -15% year on \nyear until 2020\n– Consistent with \nPurdue Finance \nassumption\n• Assume organic \ngrowth only (i.e., no \nBD deals)\n• SG&A remains the \nsame as current \nlevel\n• Nucynta sales \nremains the same as \ncurrent level – \noptimistic given it \nhas been declining \nin the past 2 years\nKey \nimplication\n• Clear nee\nto quickl\nincrease\nsales to \nreassure\ninvestors\nsales for\ndriven \nstrategy\nrisk\n• Likely ne\nbig wins \nquickly, \nrather th\nincremen\nly \nincreasin\nthrough \ntime\nDIRECTIONAL ESTIMATION\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 14 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium is more likely to bid aggressively on large national accounts to rapidly gain the $50M \nneeded to break even financially\n5\nNet sales1\n$M\n43\n11\n7\n11\n21\n31\n5\n5\n1\n1\n10\n10\n5\n1\n1\n1\n159\n18\n13\n4\n111\n73\n63\n17\n15\n6\n10\n9\n6\n113\n53\n17\n5\n545\n2019 contracting\nMarket \nsegment\nCommer-\ncial\nMedicare \nPart D\nCurrent status (FYE June 2018)\n1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; \n3 Assuming status carries over from 201807 period for \nthose accounts with OxyContin formulary access, status based on majority of lives; \n4 Excluding BCBS TN               5 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other prime accounts \n21%\n17%\n13%\n21%\n23%\n20%\n4%\n9%\n3%\n5%\n26%\n14%\n14%\n15%\n17%\n14%\nGross sales\n$M \nMarket \nShare\n11%\n7%\n6%\n2%\n2%\n1%\n1%\n1%\n1%\n1%\n11%\n5%\n2%\n1%\n1%\n0%\n54%\n% \nNet sales \nAccount\nExpress Scripts4\nCaremark\nOptumRx  - United Healthcare\nAetna Health Plans\nPrime Therapeutics - excl HCSC5\nPrime Therapeutics - HCSC\nCigna Healthcare\nProcare\nBCBS FL (Prime Therapeutics)\nIndependence BCBS (PA)\nCaremark\nOptumRx  - United Healthcare\nExpress Scripts\nPrime Therapeutics\nEnvisionRx Options\nTotal\nMedImpact\n2T Preferred\nNOF\nNOF\n2T Preferred\nNOF\n3T Preferred\n3T Pref PDP/MAPD NOF\nPref MAPD/PDP NOF\n2T Preferred\n2T Preferred\n2T Preferred \n2T Preferred\n2T Preferred\n2T Preferred\nNOF\n2T Preferred\n42%\n35%\n38%\n21%\n28%\n29%\n0%\n20%\n0%\n0%\n56%\n66%\n38%\n40%\n37%\n28%\nRebate2\nOxyContin\nXtampza ER3\nNon-preferred\nPreferred\nPreferred\nNon-preferred\nPreferred\nNOF\nPreferred\nNOF\nNOF\nNOF\nNon-preferred\nNon-preferred\nPreferred\nNon-preferred\nPreferred\nPreferred\n2019 formulary status\nCollegium is \nlikely to \ndouble down \non big \nnational \naccounts in \norder to \nachieve \nbreak-even\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\nTBD\n11/04/2018\n11/16/2018\n12/07/2018\n12/14/2018\n11/19/2018\n2020 Bid \ndue date\nSOURCE: Purdue internal data, MMIT\nLives\n$M \n102\n26\n5\n191\n21\n112\n26\n21\n992\n12\n11\n7\n6\n258\n155\n20\n8\nGiven its size \nand regional \nfocus, Prime \ncould be a \npriority \naccount for \nCollegium, \nthough not \nlikely as \ngreat as the \nlarge \nnational \naccounts\n5\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 15 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nPotential bidding options for Prime Part D\nPotential \nrebate\nInitial bid\nMaintain rebate \nrate of  40% to \ncontinue \ncurrent access \nstatus\nPotential payor \nfeedback\nAccepting the offer\nRequesting \nmoderate \nenhancement \n(≤45%)\nRequesting \nsignificant \nenhancement \n(>45%)\nProjected 2020 net \nsales ($M)\nOptions for Purdue\nReaching agreement\nIncreasing rebate \nrate by a couple of \npercentage points \nPulling back rebate \nfor parity with \nXtampza (30-35%) \nIncreasing rebate \nrate to >45%\nPulling back rebate \nfor parity with \nXtampza (35-40%)\nWalk away\n40%\n42%\n34%\n50%\n40%\n0%\n11.2\n10.8\n10.8\n8.9\n9.6\n10.2\nMore likely in case of very \naggressive Xtampza offer (i.e., \n>70% rebate) to become the \nexclusive Oxycodone ER\nLess 2\nnet sa\nwalk-a\nbut co\nmore \nattract\nconsid\nlong te\nfinanc\nand \nintang\nimpac\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 16 ===\n \nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nAppendix\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 17 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nPrime contracting: 2020-2022 financial impact under different access scenarios\nAccess scenarios\nBoth Oxycontin and \nXtampza preferred \nXtampza preferred, \nOxycontin non-\npreferred\nContinue current \naccess status as \nexclusive preferred\noxycodone ER\nXtampza replacing \nOxycontin as \nexclusive preferred \nwith grandfathering\n51%\n41%\n34%\n5%\n0%\nOxycontin excluded \nwithout \ngrandfathering\n1\n2\n3\n4\nAssumed \nOxycontin rebate\nIncremental impact of exclusion  could be more detrimental in the longer term, due to continuing loss of share in a declining market\nShare by \nproduct, \n2020 Q4\n5\nPRIME\n15\n6\n1\n22\nOxycontin net sales2 ($M)\n1 Projected using a 3-4 ppt increase YoY on assumed likely rebate for scenarios 1-3\n2.Net sales shown exclude rebates and other gross-to-net reductions, i.e. donut hole and wholesales fees etc.\n5.8\n24.7\n10.8\n8.1\nXtampza\nOxycontin\nOther brands\n42%\n34%\n28%\n27%\n0%\n2020\n20221 \n22\n12\n7\n3\n7.1\n4.2\n10.8\n22.0\n4\n8\n11\n22\n3.4\n6.6\n10.8\n20.9\n8\n6\n8\n22\n5.6\n2.4\n10.8\n18.8\n9\n7\n6\n22\n2.0\n5.1\n17.3\n10.2\n2021\n2020\n2022\nLower blended rebate rate with fewer grandfathered \npatients  \nDeprioritize\nd scenario\n8\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n\n\n=== Page 18 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nPrime – continuing current access status or parity with Xtampza are best options to maintain \nappropriate access for patients while preserving best economics\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; \n2 Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  \n7.9\n11.2\n10.8\n11.5\n11.0\n7.2\n6.2\n11.2\n10.2\n6.6\n2020 access \nscenarios\nBoth \nOxycontin and \nXtampza \npreferred \nXtampza \npreferred, \nOxycontin \nnon-preferred\nContinue \ncurrent access \nstatus as  \nexclusive \npreferred\noxycodone ER\nXtampza \nreplacing \nOxycontin as \nexclusive \npreferred with \ngrandfathering\nOxycontin \nexcluded \nwithout \ngrandfatherin\ng\nXtampza net \nsales ($M)\n1\n2\n3\n4\n0%\n40%\n50%\n70%\n70%\nAssumed \nXtampza \nrebate\nImplication on Oxycontin bidding strategy\nexclusivity  could maximize net sales assuming no or reasonable increase in rebates, parity with Xtampza could be an attractive option – while exclusion w\n2.9\n1.8\n1.6\n1.1\n3.2\n0.8\n1.6\n2.1\nShare by \nproduct, 2020 \nQ4\nOther brand \nnet sales ($M)\n5\n8\n22\n7\n9\n5\n22\n8\n3\n10\n12\n4\n8\n11\n9\n22\n7\n6\n8\n5\n6\n8\n9\n22\n22\n9\n7\n6\n9\n3\n22\n22\n22\n8.8\n8.8\n7.3\n8.0\n7.7\n8.4\n9.2\n9.6\nOxycontin\nOther brands\nXtampza\nPRIME\n0.7\n1 6\n15\n22\n6.5\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nShar\ne \nshift\nBreak-\neven \nrebate2 \n37%\n48%\n32%\n37%\nN/A\n30%\n44%\n60%\n45%\nNet sales at min \nrebate1 ($M)\n42%\nRebate rate to keep \nPrime whole1 \n30%\n44%\n27%\n40%\nN/A\n24%\n36%\n40%\nNeed to \nmaintain \ncurrent \nrate a \nminimum\nBeing sim\n9\nSource:  https://www.industrydocuments.ucsf.edu/docs/hyfg0257\n",
    "extraction_method": "pymupdf+ocr",
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "hyfg0257-info.pdf",
    "file_path": "Presentations/hyfg0257.zip/hyfg0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - hyfg0257 - Downloaded 31/03/2025 11:11:38 AM\nDocument Information\nTitle: 20181127 Purdue market access strategy update_v1126 updated.pptx\nURL: https://www.industrydocuments.ucsf.edu/docs/hyfg0257\nAuthor: Xiaodong Zhang\nDocument Date: 2018 November 27; 2019 October 27\nType: Presentation\nGenre: Microsoft PowerPoint 2016\nPages: 18\nID: hyfg0257\nCollection: McKinsey Documents\nDrug: Oxycodone; Tapentadol\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-4857055\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nXiaodong Zhang. 20181127 Purdue market access strategy update_v1126 updated.pptx. 2018 \nNovember 27; 2019 October 27. McKinsey Documents. Unknown. https://www.\nindustrydocuments.ucsf.edu/docs/hyfg0257\nArtifacts\n1.\t hyfg0257.zip [ 844.07 kb]\n",
    "extraction_method": "pymupdf+ocr",
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T12:01:01.743953",
  "overall_success": true
}